The RIPPLE AT-PLUS Study

Launched by LIVERPOOL HEART AND CHEST HOSPITAL NHS FOUNDATION TRUST · Apr 12, 2019

Keywords

ClinConnect Summary

The RIPPLE AT-PLUS Study is looking at two different ways to perform a procedure called catheter ablation to treat atrial tachycardia, a condition where the heart beats faster than normal. This study aims to find out which method helps prevent atrial tachycardia from coming back over the long term. The trial is not yet open for participants, but it will include adults aged 18 and older who have been recommended for this procedure by their healthcare team.

To join the study, participants need to be able to give their consent and should not have any medical reasons that would make the catheter ablation unsafe for them. If you are interested in learning more about this trial or think you might be eligible, you can talk to your doctor about it. This study is an important step in improving treatment options for people with atrial tachycardia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Referred for catheter ablation of AT by the direct care team, based on clinical indication.
• • 2. Male or female, aged \>18 years old.
• • 3. Able to consent for recruitment to the trial and the catheter ablation procedure.
• Exclusion Criteria:
• • 1. Contraindication to catheter ablation as deemed by the clinical team.
• • 2. Typical atrial flutter or AF on ECG.